Navigation Links
LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available
Date:11/16/2009

diopulmonary resuscitation must be immediately available.

The following serious adverse reactions have been reported with the use of LUSEDRA.

  • Respiratory depression
    • Apnea was reported in 1/455 (< 1%) patients treated with LUSEDRA using the standard or modified dosing regimen.
  • Hypoxemia
    • Hypoxemia was reported in 20/455 (4%) patients treated with LUSEDRA using the standard or modified dosing regimen. Retention of purposeful responsiveness did not prevent patients from becoming hypoxemic following administration of LUSEDRA.
  • Loss of purposeful responsiveness
    • LUSEDRA has not been studied for use in general anesthesia. However, administration of LUSEDRA may inadvertently cause patients to become unresponsive or minimally responsive to vigorous tactile or painful stimulation. The incidence of patients who became minimally responsive or unresponsive to vigorous tactile or painful stimulation was 7/183 (4%) for colonoscopy and 24/149 (16%) for bronchoscopy. The duration of minimal or complete unresponsiveness ranged from 2 to 16 minutes in colonoscopy patients and from 2 to 20 minutes in bronchoscopy patients.
  • Hypotension
    • Hypotension was reported in 18/455 (4%) patients treated with LUSEDRA using the standard or modified dosing regimen.
    • Patients with compromised myocardial function, reduced vascular tone, or who have reduced intravascular volume may be at an increased risk for hypotension.

The use of supplemental oxygen is recommended in all patients receiving LUSEDRA. Airway assistance maneuvers may be required. LUSEDRA may produce additive cardiorespiratory effects when administered with other cardiorespiratory depressants such as benzodiazepines and narcotic analgesics. When LUSEDRA is used at greater than the recommended doses, the incidence of serious adverse reactions is increased.

'/>"/>
SOURCE Eisai Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
2. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
3. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
7. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
8. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
9. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces ... available in its catalogue: Personal ... Trends and Opportunities to 2018 ... The report provides in depth market analysis, ... accident and health insurance segment, including: - ...
(Date:8/20/2014)... -- Research and Markets has announced ... (Technology, Types, Applications, Services and Geography) - Research ... offering. A new report titled, ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020", suggests that the global biosimilars market ...
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
Breaking Medicine Technology:Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2Global Market Report of Pralmorelin 2
... Environmental testing and monitoring programs are essential ... understand industrial sterilization and contamination control procedures to bring ... In attempting to meet regulatory demands from ... Pharmacopoeia, the greatest challenge for medical device and pharmaceutical ...
... Ill., Aug. 10, 2011 John Ebeid, a ... Delta Outsourcing, a division of Delta Pharma and ... will provide the strategic direction for Delta,s outsourcing ... services, including medical writing, pharmacovigilance, clinical and medical ...
Cached Medicine Technology:"Environmental Monitoring and Certification in Controlled Environments: Meeting Regulations and Achieving Effective Microbial Control for Pharmaceutical and Medical Device Manufacturers" - New White Paper from Microtest Laboratories 2John Ebeid Joins Delta Outsourcing as Vice President 2
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 (HealthDay ... condition that causes a life-threatening irregular heartbeat, a new study ... lower risk of developing atrial fibrillation, compared to women who ... of the Journal of the American Heart Association . ... disorder even if they were obese, the study found. Obesity ...
(Date:8/20/2014)... By Kathleen Doheny ... -- Breast reconstruction after a mastectomy has long been an ... percent of women choose it. "The most common reasons ... important, they weren,t interested in more surgery or they were ... Morrow, chief of breast surgery at Memorial Sloan Kettering Cancer ...
(Date:8/20/2014)... Park Cities Pet Sitter , Inc. has announced their ... drive that benefits the animal shelter and rescue communities. ... the Humane Society of the United States’ Animal Shelter Appreciation ... As part of their participation, Park Cities Pet Sitter plans ... Presents 4 Pets drive from their client base, as well ...
(Date:8/20/2014)... 20, 2014 A common approach to treating kidney ... not improve survival chances for people who suddenly developed ... the University of Pittsburgh School of Medicine. , Their ... , suggest acute hemodialysis, an aggressive method that is ... not provide a definitive benefit to the patient. , ...
(Date:8/20/2014)... August 20, 2014 With 3943.8% growth, Connexion ... of the nation’s fastest growing companies. The Inc. 500 ranks ... care sector. Connexion Point is the #1 fastest growing company ... Medicare and Medicaid, and its clients include four of the ... employs 1,000 people and has offices and contact centers in ...
Breaking Medicine News(10 mins):Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2
... A cholesterol-lowering drug reduced the enlarged prostates of hamsters to ... benign prostatic hyperplasia (BPH), report researchers at Children,s Hospital Boston ... of Urology. Together, the drugs worked even better. "We ... that lowering cholesterol has the potential to reduce BPH in ...
... Oct. 21 (HealthDay News) -- A new study from ... pollution could increase the risk of developing severe chronic ... a link between high levels of air pollution and ... pollution exposure to the development or progression of the ...
... A new research study conducted by Boston University ... significantly improve biennial mammography screening rates among inner city ... Journal of General Internal Medicine , indicate the importance ... patient populations. Breast cancer is the second ...
... , THURSDAY, Oct. 21 (HealthDay News) -- Clenching your ... goals or resist temptations such as unhealthy desserts, a ... were faced with a number of self-control challenges, such ... a healthy but foul-tasting vinegar drink, deciding whether to ...
... 21, 2010) Telementoring may be an effective way ... in the care of patients in need of emergency ... in the September issue of the Journal of the ... general surgery residents with no formal subspecialty training participated ...
... Reporter , WEDNESDAY, Oct. 20 (HealthDay News) -- If you,re ... you might not always need to visit the doctor to ... is published in the Oct. 21 issue of the ... tests were similarly effective to monthly clinic testing for patients ...
Cached Medicine News:Health News:Cholesterol-lowering drug shrinks enlarged prostates in hamster model 2Health News:Air Pollution Ups Risk of Chronic Lung Disease: Study 2Health News:BUSM study shows patient navigations improve mammography rates in minority women 2Health News:Clenching Muscles May Boost Willpower 2Health News:Telementoring may address need for surgical subspecialty expertise in remote locations 2Health News: Home Monitoring of Blood-Thinner Use Appears Effective 2Health News: Home Monitoring of Blood-Thinner Use Appears Effective 3Health News: Home Monitoring of Blood-Thinner Use Appears Effective 4
5 mm tying platform. Round knurled handle with dull finish. Curved shafts. Overall length 3.9 inches....
Straight shafts and tips with 5.5 mm tying platform. 0.3 mm gap at platform heel. True round knurled handle in closed position with polished finish. Overall length 4.3 inches....
Curved shafts with 12 mm tying platform. Serrated handle with polished finish. Overall length 4.3 inches....
Hartman Mosquito forceps, straight, 3-1/2", German stainless steel...
Medicine Products: